SCHEMBL856468

SCHEMBL856468

Cc1nc2ccc(-c3ccc4c(c3)CN(c3ncnc5ccc(OCC#N)cc35)CCO4)cc2[nH]1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 1/20 0.44
CYP1A2 P05177 12/20 0.39
CYP3A4 P08684 12/20 0.39
CLK4 Q9HAZ1 10/20 0.39
ALDH1A1 P00352 8/20 0.39
HIF1A Q16665 8/20 0.39
LMNA P02545 7/20 0.39
CYP2C19 P33261 6/20 0.39
USP2 O75604 6/20 0.39
CYP2D6 P10635 5/20 0.39
MAPK1 P28482 5/20 0.39
MEN1 O00255 5/20 0.38
KMT2A Q03164 5/20 0.38
TSHR P16473 2/20 0.38
KDM4E B2RXH2 2/20 0.35
HPGD P15428 2/20 0.35
TOP1 P11387 1/20 0.34
TOP2A P11388 1/20 0.34
HSD17B10 Q99714 2/20 0.34
IRAK4 Q9NWZ3 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL856306 0.91 PIK3CA (0.46) PIK3CACYP1A2CYP3A4CLK4ALDH1A1
SCHEMBL858879 0.89 PIK3CA (0.45) PIK3CACYP1A2CYP3A4CLK4ALDH1A1
SCHEMBL858599 0.89 CYP2C19 (0.49) PIK3CACYP1A2CYP3A4CLK4ALDH1A1
SCHEMBL857090 0.89 PIK3CA (0.45) PIK3CACYP1A2CYP3A4CLK4ALDH1A1
SCHEMBL3763910 0.87 PRMT5 (0.45) PIK3CACYP1A2CYP3A4CLK4ALDH1A1
SCHEMBL858119 0.87 PIK3CA (0.43) PIK3CACYP1A2CYP3A4CLK4ALDH1A1
SCHEMBL857187 0.86 PIK3CA (0.51) PIK3CACYP1A2CYP3A4CLK4ALDH1A1
SCHEMBL856917 0.85 PIK3CA (0.49) PIK3CACYP1A2CYP3A4CLK4ALDH1A1
SCHEMBL856212 0.84 PIK3CA (0.49) PIK3CACYP1A2CYP3A4CLK4ALDH1A1
SCHEMBL3764793 0.84 PIK3CA (0.49) PIK3CACYP1A2CYP3A4CLK4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8648066-B2 Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture EXELIXIS, INC. (US) 2014-02-11 US claimed
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-03-20 US disclosed
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-03-20 US disclosed
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-03-20 US disclosed
US-8648066-B2 Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture EXELIXIS, INC. (US) 2014-02-11 US disclosed
US-8648066-B2 Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture EXELIXIS, INC. (US) 2014-02-11 US disclosed
US-8648066-B2 Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture EXELIXIS, INC. (US) 2014-02-11 US disclosed
EP-2432779-A1 BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES Exelixis, Inc. (US) 2012-03-28 EP disclosed
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2010-11-25 US disclosed
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2010-11-25 US disclosed
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2010-11-25 US disclosed
WO-2010135524-A1 BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES EXELIXIS, INC. (US) 2010-11-25 WO disclosed
WO-2010135524-A1 BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES EXELIXIS, INC. (US) 2010-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA PIK3CA 3/4885CYP1A2 997/4885CYP3A4 493/4885
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA PIK3CA 3/4885CYP1A2 1244/4885CYP3A4 652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.